CLINICAL LAB SCIENEC

INDEX 479
Technical medical laboratory workers,
credentialing and certification
of, 17, 18t
Technician(s), job descriptions for,
32–33
Technician-level medical laboratory
worker, described, 32
Technicon, 365
Technologist(s), job descriptions for,
32–33
Temperature conversions,
214, 214f
formula for, 214, 215t
10-fold compound dilution, 406,
406f
Terroristic threat response
procedures, safety measures
related to, 108–109, 109t
The Joint Commission (TJC), 34, 49
on QA, 232
Thromboplastin, 329
Thrush, 388
Tinea pedis, infections due to, 388
Tissue Committee, 85t, 86
TJC. See The Joint Commission
(TJC)
TNTC (too numerous to count), 304
To contain pipette (TC), 195
To deliver pipette (TD), 194–195
Too numerous to count (TNTC),
304
Total cholesterol, determination of,
375–378
equipment and supplies, 375–376
linearity, 378
principles, 375
procedure, 376–378
QC, 378
reporting of results, 378
Total protein
albumin in, 369
determination of, 368–372, 369f,
370f
equipment and supplies, 370,
370f
linearity, 372
principles, 368–369, 369f,
372–373
procedure, 370–371
QC, 372
reporting of results, 372
plasma in, 369
Tourniquet(s), for venipuncture,
273f
application of, 276–277, 277f,
278f
Toxic chemicals, disposal of, policies
for, 95–97, 96f–98f
Toxic materials, spills of, exposure
through, 127–128
Transfer pipettes, 192
Transfusion(s), blood, 415, 417
Trend(s), defined, 236t, 244
Triage MeterPlus, 170f
Trichloroacetic acid (TCA), 314
Trichomonas spp.
cells of, 305f
in urine, 301
Triple phosphate crystals, 307f
t-test, 248, 249, 249t
Tube(s), indirect (reverse) grouping
by, 426–427, 427f. See also
Immunohematology (blood
banking), indirect (reverse)
grouping by tube
Tube test, for Rh factor, procedure,
429f, 430
Tuberculosis (TB), 112
assessment of, 146t
characteristics of, 146t
diagnostic tests for, 140, 141f,
146t
exposure to, described, 143–144
in health care setting, 139–146,
141f, 142f, 146t
introduction to, 139–142, 141f,
142f
prevention of
HEPA filter masks in, 142,
142f, 143
workplaces covered by guidelines,
143, 144
reservoir for, 141
transmission of, 141, 142f
occupational exposure to, workers
most at risk for, 144, 145
organism causing, 140
pathogenesis of, 146t
postexposure treatment and
follow-up for, 145
prevention of
BCG in, 144
education and training required
for faculty and students in,
146, 146t
PPD in, first-time positive reaction
to, 144–145
PPE in, 142–143
symptoms and signs of, 140–141
transmission of, modes of, 146t
Tubular resorption, 313
Twin-plot graph of Youden, modified
by Tonks, 236
Two-consecutive control rule, 244
Two-fold dilution series, 405, 405f
2% to 5% cell suspension preparations,
419–422. See also
Immunohematology (blood
banking), 2% to 5% cell
suspension preparations
Tyrosine crystals, 308f
U
Unassayed controls, defined, 246
Universal precautions, in
bloodborne- and airborne
pathogen–related infection
prevention, 150
Unopette disposable diluting pipette
system. See Unopette system
Unopette system, for WBC count,
355–360, 356f–358f
equipment and supplies, 355–356,
356f
principles, 355
procedure, 356–359, 357f, 358f
reporting of results, 359–360
Uric acid crystals, 307f
Urinalysis, 287–324
chemical, 293–294, 293f, 294f
in clinical laboratory, 11, 11f
complete, rationale for, 288–290,
289f, 290t
confirmatory tests for positive
urinary chemistry findings,
308–309
macroscopic, 293
microscopic, 294–295, 295f,
301–309, 303f, 304t, 305f,
306t, 307f, 308f, 309t
procedures for, 293–322. See also
Urine; Urine samples
Acetest, 309–310, 310f
Copyright 2010 Cengage Learning. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s).
Editorial review has deemed that any suppressed content does not materially affect the overall learning experience. Cengage Learning reserves the right to remove additional content at any time if subsequent rights restrictions require it.